Amvis : Q3Financial Highlights （1,076KB）

Third Quarter of the Fiscal Year Ending September 30, 2023

Financial Highlights

Amvis Holdings, Inc.

August 9, 2023

©Amvis Holdings, Inc.

Establishing Sustainable Mechanisms and Businesses through Which We Can Address Social Problems

Social Problem-Solving Business

Acceptance

of

Patients

Opening of		Provision of
New		Necessary
Facilities	Social	Medical Care
	Problem-
	solving

ProfitabilityOperational

ImprovementImprovements

Under the government's policy of shortening of hospital stays and returning home, Ishinkan has been actively accepting patients who are unsure of where to go after being discharged from medical facilities, including those in the terminal stages of cancer, those who need respiratory care (are on respirators, have had tracheostomies, etc.), and those with neurodegenerative diseases. Meanwhile, we have remained conscious of our role as an organization that supports the successful functioning of regional healthcare and have endeavored to fulfill this role by, in principle, ensuring that patients can continue to be seen by their existing primary physicians and care managers.

In order to satisfy our duty to support regional healthcare, we aim to further expand the Ishinkan business. Also, we plan to focus more on strengthening and revitalizing regional healthcare by providing various support for exhausted medical institutions and care providers, utilizing the know-how and human resources acquired through the Ishinkan business.

We hope our business will help to solve the medical problems of revitalizing regional healthcare, reducing the exhaustion of medical workers, and alleviating regional disparities in healthcare and to enhance the medical and care system, which is the goal of the government.

©Amvis Holdings, Inc.	2

Backed by Strong Demand, the Pace of New Openings in FY24 Exceeds Our Assumed Progress under the Three-year Plan

FY23 Q3 YTD Operating Performance

Q3 YTD Net Sales (Actual)		Q3 YTD Operating Profit (Actual)

JPY 22.9bn	JPY 6.1bn
(Operating margin: 26.9%)

Full-Year Net Sales (Forecast)		Full-Year Operating Profit (Forecast)

JPY 30.6bn	JPY 7.8bn
(Progress toward full-year	(Progress toward full-year
forecast: 75.0%)	forecast: 78.5%)

©Amvis Holdings, Inc.	3

Financial Highlights

• The utilization rate at existing facilities was 86.6%, surpassing our target for stable operations (82-85%). The start of new facilities was also favorable. As a result, Q3 YTD performance progressing steadily against full-year forecasts.
• • Net sales: JPY 22.9bn (Progress toward full-year forecast: 75.0%)
  • Operating profit: JPY 6.1bn (Progress toward full-year forecast: 78.5%)
  • Net profit: JPY 4.6bn (Progress toward full-year forecast : 85.4%)
• In Q3, we opened 5 new facilities. As a result, we had 70 facilities (3,446 beds) as of June 30, 2023. Although, until FY22, we limited the number of facility openings in Q4, we plan to open 6 new facilities, 2 in August and 4 in September, and expand 1 facility in FY23 Q4.
• Toward the target of 127 facilities (by September 30, 2025) set in Amvis 2025, we have already announced plans to open 25 new facilities and expand 1 facility (1,308 beds) in FY24, exceeding the target of 23 new facilities (1,161 beds) for FY24 set in the three-year plan.
• • We have already decided to open 10 new facilities in Tokyo during FY23 and FY24.
  • We are expanding in Western Japan as well, deciding to open 2 new facilities in Western Japan in FY24, 1 in Osaka Prefecture and 1 in Okayama Prefecture.
• Based on inflation of wood, energy resources and goods used at the facilities, we raised patient payments by about 7,000 yen per month in FY23, and plan to raise them again by about 4,000 yen per month in October 2023.

©Amvis Holdings, Inc.	4

Net Sales and Profit Rose Steadily

as the Number of Facilities and Bed Capacity Increase

• Net sales and operating profit increased compared to Q3 YTD of FY23 as the number of bed capacity increased by 27%.
• Progress toward full-year forecast was favorable on net sales (75.0%) and operating profit (78.5%). Net profit progressed at a high rate (85.4%) due to the impact of extraordinary income.

Q3 YTD Performance and Progress Toward FY23 Forecasts

Net Sales

(JPY MM / ％)
	30,682
23,072			22,999
		16,410
			＋40.2%
FY22	FY23	FY22	FY23
	（forecast）	Q3	Q3
		EBITDA
30.2%	29.7%	30.5%	30.6%
	9,116		7,035
6,967
	5,000
		＋40.7%
FY22	FY23	FY22	FY23
	（forecast）	Q3	Q3

Note:

1. Excluding extraordinary income / losses, the profits growth rate is 41.8%.

Operating Profit

：Percentage of Net Sales	26.8%	26.9%
26.6%	25.7%
6,132	7,872		6,176
		4,398	＋40.4%
FY22	FY23	FY22	FY23
	（forecast）	Q3	Q3

Net Profit

18.5%	17.6%	18.6%	20.1%
4,279	5,402		4,614
		3,055 ＋51.0%(1)
FY22	FY23	FY22	FY23
	（forecast）	Q3	Q3

©Amvis Holdings, Inc.	5